vs
GENMAB A/S（GMAB）与罗致恒富（RHI）财务数据对比。点击上方公司名可切换其他公司
罗致恒富的季度营收约是GENMAB A/S的1.4倍（$1.3B vs $925.0M），GENMAB A/S同比增速更快（18.7% vs -5.8%），GENMAB A/S自由现金流更多（$327.0M vs $170.8M）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
罗致恒富是1948年成立的国际人力资源咨询机构，总部位于加利福尼亚州门洛帕克和圣拉蒙，是全球规模领先的会计与金融领域人才派遣服务商之一，在全球范围内设有超过345个办公点。
GMAB vs RHI — 直观对比
营收规模更大
RHI
是对方的1.4倍
$925.0M
营收增速更快
GMAB
高出24.5%
-5.8%
自由现金流更多
GMAB
多$156.2M
$170.8M
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $1.3B |
| 净利润 | $336.0M | — |
| 毛利率 | 93.8% | 37.6% |
| 营业利润率 | 38.9% | 1.7% |
| 净利率 | 36.3% | — |
| 营收同比 | 18.7% | -5.8% |
| 净利润同比 | 65.5% | — |
| 每股收益（稀释后） | $5.42 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABRHI
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | $925.0M | $1.4B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | $779.0M | $1.5B | ||
| Q1 24 | — | $1.5B |
净利润GMABRHI
| Q4 25 | — | — | ||
| Q3 25 | — | $42.9M | ||
| Q2 25 | $336.0M | $41.0M | ||
| Q1 25 | — | $17.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $65.5M | ||
| Q2 24 | $203.0M | $68.2M | ||
| Q1 24 | — | $63.7M |
毛利率GMABRHI
| Q4 25 | — | 37.6% | ||
| Q3 25 | — | 37.2% | ||
| Q2 25 | 93.8% | 37.2% | ||
| Q1 25 | — | 36.9% | ||
| Q4 24 | — | 38.8% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | 96.4% | 39.2% | ||
| Q1 24 | — | 38.1% |
营业利润率GMABRHI
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | 38.9% | 0.1% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | 4.7% | ||
| Q3 24 | — | 4.1% | ||
| Q2 24 | 30.3% | 5.1% | ||
| Q1 24 | — | 2.8% |
净利率GMABRHI
| Q4 25 | — | — | ||
| Q3 25 | — | 3.2% | ||
| Q2 25 | 36.3% | 3.0% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | 26.1% | 4.6% | ||
| Q1 24 | — | 4.3% |
每股收益（稀释后）GMABRHI
| Q4 25 | — | $0.32 | ||
| Q3 25 | — | $0.43 | ||
| Q2 25 | $5.42 | $0.41 | ||
| Q1 25 | — | $0.17 | ||
| Q4 24 | — | $0.53 | ||
| Q3 24 | — | $0.64 | ||
| Q2 24 | $3.13 | $0.66 | ||
| Q1 24 | — | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $464.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.3B | $1.3B |
| 总资产 | $6.5B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GMABRHI
| Q4 25 | — | $464.4M | ||
| Q3 25 | — | $365.3M | ||
| Q2 25 | $1.3B | $380.5M | ||
| Q1 25 | — | $342.5M | ||
| Q4 24 | — | $537.6M | ||
| Q3 24 | — | $570.5M | ||
| Q2 24 | $622.0M | $547.4M | ||
| Q1 24 | — | $540.9M |
股东权益GMABRHI
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $5.3B | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | $4.4B | $1.5B | ||
| Q1 24 | — | $1.5B |
总资产GMABRHI
| Q4 25 | — | $2.9B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | $6.5B | $2.8B | ||
| Q1 25 | — | $2.7B | ||
| Q4 24 | — | $2.9B | ||
| Q3 24 | — | $3.0B | ||
| Q2 24 | $5.6B | $2.9B | ||
| Q1 24 | — | $2.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $182.5M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | $170.8M |
| 自由现金流率自由现金流/营收 | 35.4% | 13.1% |
| 资本支出强度资本支出/营收 | 2.4% | 0.9% |
| 现金转化率经营现金流/净利润 | 1.04× | — |
| 过去12个月自由现金流最近4个季度 | — | $266.8M |
8季度趋势，按日历期对齐
经营现金流GMABRHI
| Q4 25 | — | $182.5M | ||
| Q3 25 | — | $77.4M | ||
| Q2 25 | $349.0M | $119.4M | ||
| Q1 25 | — | $-59.3M | ||
| Q4 24 | — | $154.8M | ||
| Q3 24 | — | $129.6M | ||
| Q2 24 | $438.0M | $142.0M | ||
| Q1 24 | — | $-15.9M |
自由现金流GMABRHI
| Q4 25 | — | $170.8M | ||
| Q3 25 | — | $63.6M | ||
| Q2 25 | $327.0M | $104.2M | ||
| Q1 25 | — | $-71.7M | ||
| Q4 24 | — | $140.5M | ||
| Q3 24 | — | $111.8M | ||
| Q2 24 | $430.0M | $129.6M | ||
| Q1 24 | — | $-27.7M |
自由现金流率GMABRHI
| Q4 25 | — | 13.1% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | 35.4% | 7.6% | ||
| Q1 25 | — | -5.3% | ||
| Q4 24 | — | 10.2% | ||
| Q3 24 | — | 7.6% | ||
| Q2 24 | 55.2% | 8.8% | ||
| Q1 24 | — | -1.9% |
资本支出强度GMABRHI
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | 2.4% | 1.1% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | 1.0% | 0.8% | ||
| Q1 24 | — | 0.8% |
现金转化率GMABRHI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | 1.04× | 2.91× | ||
| Q1 25 | — | -3.42× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | 2.16× | 2.08× | ||
| Q1 24 | — | -0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
